Yes, you can sell the same formula in both the US and the EU, but the compliance pathway, labeling, and in some cases the permissible ingredient concentrations are different in each market, which means the same physical product requires different labeling and potentially different manufacturing documentation for each territory.
In the US under MoCRA, your pore serum is a cosmetic (unless it contains OTC actives like salicylic acid above 0.5% with drug claims). You need FDA facility registration and product listing, a compliant INCI-labeled ingredient list in descending order of concentration, and English-language labeling meeting 21 CFR Part 701. No pre-market safety submission is required, though you must maintain an internal safety substantiation file.
In the EU, the same formula must go through a Cosmetic Product Safety Report (CPSR) prepared and signed by a qualified safety assessor (typically a toxicologist with relevant credentials). You need to appoint a Responsible Person (RP) who is a legal entity established in the EU — this can be a third-party RP service, which costs roughly €300 to €800 per product annually. The product must be notified in the CPNP (Cosmetic Products Notification Portal) before the first EU sale or distribution. INCI labeling is required in the local language(s) of each member state where you sell — multi-language labels are standard for pan-EU distribution.
The ingredient-level conflict most commonly affects salicylic acid and retinol. If your US serum contains salicylic acid at 1% (an OTC active in the US for acne), that concentration is at the maximum restricted limit for EU leave-on products under Annex III, and it requires specific label warnings in the EU that do not appear on your US Drug Facts panel. Retinol above 0.3% in a leave-on product is under proposed EU restriction and may require reformulation for EU distribution.
Nano-ingredients (silica microspheres below 100 nm) must be disclosed with [nano] in the EU INCI list — a requirement that does not exist in US labeling.
The practical path for a dual-market launch is to formulate conservatively — stay below EU restriction thresholds for salicylic acid, use retinol at or below 0.3%, and confirm particle size on any silica you specify — so the same formula clears both markets. Then run two parallel compliance tracks: MoCRA registration for the US and CPSR plus CPNP for the EU. Budget an additional €1,500 to €3,000 for EU compliance on top of your US launch costs.
Working with manufacturers who already have EU-experienced formulators and can provide CPSR-ready technical documentation saves significant time. AJ Cosmo Labs lists manufacturers with EU compliance capability, so you can filter for partners who understand both markets before committing to a development agreement.
Ingredients in this answer: Salicylic Acid · Retinol
Read the full guide on Private Label Pore Minimizing Serum Manufacturer Low MOQ →